Skip to content
AnalystLens

CBRE GROUP, INC. 8-K Report, Financial Results (Nov 10, 2004)

Reports
Earnings & Results
Filing Date
Filed November 10, 2004
Period End
November 4, 2004
Security
CBRE
In the record · 2016–202610-K1110-Q328-K149

CBRE filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 149 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’17Mar ’17
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Jul ’21Jul ’21
  4. Leadership change8-K · Aug ’25Aug ’25

Summary

Summary of the 8-K filed November 10, 2004. Cited figures are marked; the original filing is the authoritative source.

CB Richard Ellis Group, Inc. (CBRE) filed this Form 8-K on November 10, 2004 to furnish the transcript of its third-quarter 2004 earnings conference call, held November 4, 2004.

The filing contains no new financial statements; the substance is management's commentary. Third-quarter revenue reached $575 milliona, up 36% year over year and 24% organic growth, which management described as the eighth straight quarter of double-digit organic revenue growth. Reported GAAP net income was $11.9 million ($0.16 diluted EPS), versus a net loss of $28.4 million a year earlier.

Excluding one-time items tied to the Insignia acquisition and the IPO, net income was $29.7 millionb and adjusted diluted EPS was $0.40, compared with $0.04 in the prior-year quarter. Profitability improved meaningfully. Adjusted operating margin was 9.4% versus 6.7% a year earlier, and management attributed the gain to revenue growth, overhead leverage, and roughly $40-42 million of annualized Insignia synergy savings.

Cash stood at $147.9 millionc at September 30, 2004, the revolver was undrawn, and the net debt to EBITDA multiple fell to 1.9x from 2.8x at year-end 2003. Management reiterated 2004 guidance of about $2.2 billion in revenue and adjusted diluted EPS of $1.50-$1.55, after including roughly $0.76-$0.81 of GAAP EPS. It also set out a 2005 framework of 7-9% revenue growth, 12-14% EBITDA growth, and EPS growth in the high teens to low 20s percent, while noting that formal 2005 budget figures were not yet final.

For investors, the key points are the strong organic growth, the margin expansion driven by operating leverage, and the deleveraging. Risks worth weighing include the sensitivity of transaction-based revenue to the real estate cycle, reliance on broker retention and productivity in competitive markets, and the material size of one-time integration and IPO-related charges in reported GAAP results. This document is a transcript of an earnings call rather than a formal financial disclosure, so the figures are management's characterizations and should be checked against the accompanying earnings release and the Form 10-Q.

Key Highlights

  1. Q3 2004 revenue of $575M, up 36% year over year and 24% organic, the eighth consecutive quarter of double-digit organic growth.
  2. GAAP diluted EPS of $0.16 (net income $11.9M) versus adjusted diluted EPS of $0.40 (net income $29.7M) after excluding Insignia acquisition and IPO-related one-time items totaling about $0.24 per share.
  3. Adjusted operating margin expanded to 9.4% from 6.7% a year earlier, driven by revenue growth, overhead leverage, and Insignia synergy savings of about $40-42M annualized.
  4. Balance sheet strengthened: cash of $147.9M at September 30, 2004, a zero revolver balance, and net debt/EBITDA of 1.9x versus 2.8x at year-end 2003.
  5. FY2004 guidance reiterated: revenue of about $2.2B and adjusted diluted EPS of $1.50-$1.55; GAAP EPS of $0.76-$0.81 after one-time costs.
  6. Preliminary 2005 outlook: revenue growth of 7-9%, EBITDA growth of 12-14%, and EPS growth in the high teens to low 20s percent, with the formal budget still in process.
  7. Market share gains: CBRE accounted for 15.4% of investment sales in the first nine months of 2004, versus 8.9% for its nearest competitor, per Real Capital Analytics.

Frequently Asked Questions

  1. Why is there such a large gap between GAAP EPS ($0.16) and adjusted EPS ($0.40) for Q3 2004?

    The gap reflects non-recurring items tied to the Insignia acquisition and the IPO. These included $11.0M of debt extinguishment costs, $4.9M of merger and integration charges, $1.7M of amortization of Insignia net revenue backlog, and $0.2M of IPO-related compensation, which together came to roughly $0.24 per share. Management presents the adjusted figure to show normalized performance, but investors should weigh the GAAP number as well, since some of these costs recur in different forms.

  2. What is driving the revenue growth at CBRE?

    Growth came mainly from transaction activity. Investment property sales rose 43% in the quarter and 32% year to date, and leasing rose 22% in the quarter and 11% year to date. Management attributed this to a stronger economy, low interest rates, growing investor capital flowing into real estate, and improving leasing fundamentals, including positive net absorption in many markets. The Insignia acquisition also contributed to reported revenue growth.

  3. Is CBRE's debt position improving?

    Yes. Net debt to EBITDA fell to 1.9x at September 30, 2004 from 2.8x at December 31, 2003. The revolver was undrawn, and management said it did not expect revolver borrowing for the rest of 2004. Management also targets reducing debt by about $50M per year, funded by internal cash flow estimated at around $113M for 2004. Some debt was paid down with IPO proceeds or through open-market purchases of its 11¼% senior subordinated notes.

  4. What risks should investors consider?

    Key risks include the cyclical nature of transaction-based revenue, which depends on real estate investment and leasing activity; the need to retain top producers in competitive markets such as New York, where rivals such as Trammell Crow have been recruiting brokers; and the difficulty of integrating acquired businesses such as Insignia. The call also noted that owner-REITs may face declining rent rolls through 2005, which could affect the broader sector even as CBRE's commission-based model benefits. The forward-looking statements disclaimer warns that actual results may differ materially.